Contents What Defines a High-Potency Active Pharmaceutical Ingredient Programme? Occupational Exposure Classification and Containment Strategy Small Molecule Formulation Expertise Analytical Development and Method Validation Technology Transfer and Scale-Up Readiness Regulatory and Good Manufacturing Practice Compliance Integration Across the Development-to-Supply Pathway […]
How to Assess Pre-Filled Syringe CDMO Readiness Contents What Makes a CDMO Ready for Pre-Filled Syringe Technology Transfer? Aseptic Fill-Finish Infrastructure Container Format Compatibility and Platform Syringe Systems Automated Inspection and Zero-Defect Quality Standards Regulatory Certification and Multi-Market Readiness Commercial […]
For commercial pre-filled syringe manufacturing in Europe, a CDMO should combine five essential capabilities: proven sterile fill-finish expertise, prefilled syringe and device know-how, validated commercial-scale capacity, mature European GMP quality systems, and robust release testing and supply continuity. These capabilities […]
Sterile fill-finish capacity is one of the most critical outsourcing decisions in injectable drug development. For pharmaceutical and biotech companies, the challenge is not only to find a contract manufacturer able to fill a Phase I clinical batch. The real […]
Outsourcing commercial manufacturing is never only a capacity decision. For creams, gels, ointments and non-sterile liquids, it is a quality, supply continuity and patient safety decision. A sponsor can transfer a formula, a method and a target batch size. What […]
Selecting a CDMO for high-potency active pharmaceutical ingredient development requires more than checking whether a partner “handles HPAPIs”. Pharma and biotech teams need to understand whether the CDMO can combine formulation expertise, proven containment, analytical development, GMP manufacturing, cleaning validation […]
Get notified on our latest news.
